What is Leerink Partnrs’ Forecast for AXSM FY2028 Earnings?
Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...
Axsome Therapeutics price target raised to $200 from $190 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...
Yahoo Finance4d
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.73 per share a year ago. These figures ...
Axsome Therapeutics price target raised to $200 from $190 at Truist
Truist raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares. The company’s Q4 ...
Nasdaq4d
AXSOME THERAPEUTICS Earnings Results: $AXSM Reports Quarterly Earnings
AXSOME THERAPEUTICS ($AXSM) posted quarterly earnings results on Tuesday, February 18th. The company reported earnings of -$0.96 per share, beating estimates of -$1. ...
Yahoo Finance3d
Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
Axsome Therapeutics Inc (NASDAQ:AXSM) reported strong financial performance with total net product revenue of $386 million for 2024, reflecting high double-digit year-over-year growth. The company ...
Seeking Alpha4d
AXSM Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...